Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trialResearch in context

Summary: Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with dismal outcomes. We conducted an open-label, phase 2 nonrandomised, externally controlled study to evaluate the efficacy and safety of targeted agents plus CHOP (cyclophosphamide, doxorubicin, vincristine, and pr...

Descripción completa

Detalles Bibliográficos

Autores principales:	Ming-Ci Cai, Shu Cheng, Hong-Mei Jing, Yan Liu, Guo-Hui Cui, Ting Niu, Jian-Zhen Shen, Liang Huang, Xin Wang, Yao-Hui Huang, Li Wang, Peng-Peng Xu, Wei-Li Zhao
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2024-09-01
Colección:	The Lancet Regional Health. Western Pacific
Materias:	Peripheral T-cell lymphoma Decitabine Azacytidine Tucidinostat Lenalidomide CHOP
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S2666606524001548
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!